<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377349</url>
  </required_header>
  <id_info>
    <org_study_id>116945</org_study_id>
    <secondary_id>2014-001119-38</secondary_id>
    <nct_id>NCT02377349</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix™ (263855) in Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the immunogenicity and safety of Boostrix™ when
      compared to a placebo given during 27-36 weeks of gestation in healthy women aged 18-45
      years. Infants born to mothers enrolled in this study will be followed-up in two separate
      clinical studies: 201330 [DTPA (BOOSTRIX)-048 PRI] and 201334 [DTPA (BOOSTRIX)-049 BST: 048].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol was amended to include Spain in the study. The reasons for the Spain-specific
      amendment are listed below:

        -  Based on the feedback from the Spanish Ethics Committee, the evaluation related to the
           acceptance of cocooning was added in the protocol.

        -  The objectives and endpoints to include cocooning were added in the protocol.

        -  The eligibility criteria for participation of household contacts were defined in the
           protocol.

        -  The study procedures for household contacts were included.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2015</start_date>
  <completion_date type="Actual">October 24, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Concentrations Against Pertussis Toxoid Antigen (Anti-PT), Filamentous Haemagglutinin Antigen (Anti-FHA) and Pertactin Antigen (Anti-PRN) in Cord Blood Samples</measure>
    <time_frame>At delivery - Visit 3 (anytime after 28 weeks of gestation)</time_frame>
    <description>Antibody concentrations were assessed by Enzyme-linked immunosorbent assay (ELISA), tabulated as Geometric Mean Concentrations (GMCs) and expressed in International units per mililiter (IU/mL) for the following assay cut-offs: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects by Pregnancy Outcomes</measure>
    <time_frame>From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).</time_frame>
    <description>Pregnancy outcomes included live birth with no congenital anomalies, live birth with congenital anomalies, still birth with no congenital anomalies, still birth with congenital anomalies, elective termination with no congenital anomalies and elective termination with congenital anomalies. No subjects with still birth or elective termination of infant were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Listed Pregnancy/Neonate Related Adverse Events of Interest</measure>
    <time_frame>From Day 0 (Visit 1) to Month 2 post-delivery (Visit 4, end of the study).</time_frame>
    <description>Listed pregnancy-related adverse events of interest/ neonate-related events of interest included gestational diabetes, pregnancy-related hypertension, premature rupture of mem-branes, preterm premature rupture of membranes, premature labour, premature uterine contractions, intrauterine growth restriction/poor foetal growth, pre-eclampsia, eclampsia, vaginal or intrauterine haemorrhage, maternal death, preterm birth, neonatal death, small for gestational age, neonatal hypoxic ischaemic encephalopathy and failure to thrive/growth deficiency were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Seroprotected Subjects Against Diphteria Antigen (Anti-D), Tetanus Antigen (Anti-T) and of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN</measure>
    <time_frame>One month post vaccination (Day 30) during pregnancy</time_frame>
    <description>A seroprotected subject against diphteria and tetanus was a subject with antibody concentration ≥ 0.1 IU/mL. A seropositive subject was a subjects with antibody concentration ≥ 2.693 IU/mL for anti-PT, ≥ 2.046 IU/mL for anti-FHA and ≥ 2.187 IU/mL for anti-PRN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-D, Anti-T, Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</measure>
    <time_frame>One month post vaccination (Day 30) during pregnancy</time_frame>
    <description>Antibody concentrations were determined by ELISA, tabulated as GMCs and expressed in IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Vaccine Response to Anti-D and Anti-T</measure>
    <time_frame>One month post vaccination (Day 30) during pregnancy</time_frame>
    <description>Vaccine response for anti-D and anti-T was defined as:
for initially seronegative subjects (S-) with pre-vaccination concentration below cut-off: &lt; 0.1 IU/mL) was an antibody concentration at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL); for initially seropositive subjects (S+) with pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Vaccine Response to Anti-PT, Anti-FHA and Anti-PRN</measure>
    <time_frame>One month post vaccination (Day 30) during pregnancy</time_frame>
    <description>Vaccine response to PT, FHA and PRN antigens is defined as: for subjects with pre-vaccination antibody concentration below the assay cut-off (S-), post-vaccination anti-body concentration ≥ 4 times the assay cut-off; for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off (S+), post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and for subjects with pre-vaccination antibody concentration ≥4 times the assay cut-off (S+), post-vaccination antibody concentration ≥2 times the pre-vaccination antibody concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN in the Cord Blood Samples</measure>
    <time_frame>At delivery - Visit 3 (anytime after 27 eligible weeks of gestation)</time_frame>
    <description>For this assay the anti-PT, anti-FHA and anti-PRN seropositivity status was determined from the cord blood samples. The seropositivity cut-offs were the following: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Solicited Local Adverse Events (AEs)</measure>
    <time_frame>During the 8-day (Day 0-Day 7) follow-up period after vaccination during pregnancy</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. &quot;Any&quot; = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Solicited General AEs</measure>
    <time_frame>During the 8-day (Day 0-Day 7) follow-up period after vaccination during pregnancy</time_frame>
    <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache and fever [defined as oral, axillary or tympanic temperature ≥ 37.5 degrees Celsius (°C) or rectal temperature ≥ 38.0 °C]. &quot;Any&quot; = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Unsolicited AEs</measure>
    <time_frame>Within 31 days (Day 0 - Day 30) after each vaccination</time_frame>
    <description>An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants With Unsolicited AEs</measure>
    <time_frame>From delivery to Month 2 post delivery (Visit 4, end of the study).</time_frame>
    <description>An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious AEs (SAEs)</measure>
    <time_frame>From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).</time_frame>
    <description>A SAE was any untoward medical occurrence that resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Household Contacts of the Infants Born to Pregnant Women Vaccinated in Spain</measure>
    <time_frame>From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).</time_frame>
    <description>This analysis assessed the vaccination status of the household contacts (who accepted, received or refused vaccination) and also the reasons for refusal (not coming to site, refused to be vaccinated, unspecified) as part of an assessment of cocooning among the eligible household contacts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Household Contacts With SAEs</measure>
    <time_frame>During the 31-day (Days 0-30) follow-up period post-vaccination (Boostrix administered preferably 2 weeks before the birth of the infant, Visit 3).</time_frame>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">688</enrollment>
  <condition>Diphtheria-Tetanus-acellular Pertussis Vaccines</condition>
  <arm_group>
    <arm_group_label>dTpa Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Boostrix™</intervention_name>
    <description>One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>dTpa Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>dTpa Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for study subjects:

          -  Subjects who, in the opinion of the investigator, can and will comply with the
             requirements of the protocol.

          -  Written informed consent obtained from the subject prior to performing any study
             specific procedure, as per local regulations.

          -  A healthy pregnant woman between, and including, 18 and 45 years of age at the time of
             screening.

          -  Pregnant subjects at 27 0/7-36 6/7 weeks (completed 27 weeks but not 37 weeks) of
             gestation at the time of vaccination (Visit 1), as established by ultrasound
             examination.

          -  Not at high risk for complications, as determined by the obstetrical algorithm for
             identification of eligible subjects and the Obstetrical Risk Assessment Form.

          -  No significant foetal abnormalities, as observed by the level II ultrasound testing
             conducted after 18 weeks of gestation.

          -  Nuchal translucency scan, serum testing and any other prenatal tests, if conducted,
             should suggest normal pregnancy.

          -  Willing to have the infant born immunised with Infanrix hexa and Prevenar 13, as per
             national recommendations, in the follow-up clinical studies DTPA (BOOSTRIX)-048 PRI
             and DTPA (BOOSTRIX)-049 BST: 048.

          -  Subjects who do not plan to give their child for adoption or place the child in care.

        Inclusion criteria for household contacts in Spain:

          -  Household contacts living in the same house as that of the infant.

          -  Household contacts or parent(s)/LAR(s) of the household contacts who, in the opinion
             of the investigator, can and will comply with the requirements of the protocol (e.g.
             reporting of SAEs).

          -  Written informed consent obtained from the household contacts or the parent(s)/LAR(s)
             prior to vaccination, as per local regulations.

          -  Household contacts who are eligible to receive a booster dose of DTP-containing
             vaccine according to the Summary of Product Characteristics (SmPC) of Boostrix and
             according to the local governmental recommendations in Spain.

          -  Female household contacts of non-childbearing potential may be enrolled in the study.

             - Non-childbearing potential is defined as pre-menarche, current tubal ligation,
             hysterectomy, ovariectomy or post-menopause.

          -  Female household contacts of childbearing potential may be enrolled in the study , if
             the household contact

               -  has practiced adequate contraception for 30 days prior to vaccination,

               -  has a negative pregnancy test on the day of vaccination and

               -  has agreed to continue adequate contraception for 2 months after receiving the
                  vaccine dose.

        Exclusion Criteria for study subjects:

          -  Subjects diagnosed with multiple pregnancies (twins, triplets etc.).

          -  Previous vaccination containing diphtheria, tetanus or pertussis antigens or
             diphtheria and tetanus toxoids at any time during the current pregnancy.

          -  Women with co-morbid medical or obstetric conditions that in the opinion of the
             investigator have the potential to complicate the pregnancy course and outcomes.

          -  Gestational diabetes as determined by glucose tolerance test conducted after 20 weeks
             of gestation, as per local recommendations of the country.

          -  History of early onset (&lt;34 weeks of gestation) of eclampsia/pre-eclampsia in previous
             pregnancy.

          -  History of major congenital anomalies in previous pregnancies.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine anytime during the current pregnancy or planned use during the study
             period.

          -  Any medical condition that in the judgment of the investigator would make
             intramuscular injection unsafe.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs during
             the period starting six months prior to the first vaccine. For corticosteroids, this
             will mean prednisone ≥20 mg/day, or equivalent. Inhaled and topical steroids are
             allowed.

          -  Administration of long-acting immune-modifying drugs at any time during the study
             period.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             in the period within the period starting 30 days before and 30 days after the dose of
             vaccine with the exception of seasonal influenza vaccine that can be administered
             anytime during the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational vaccine/product (pharmaceutical product or device).

          -  Serious underlying medical condition [e.g., immunosuppressive disease or therapy,
             human immunodeficiency virus infection, collagen vascular disease, epilepsy, diabetes
             mellitus, chronic hypertension, moderate to severe asthma, lung/heart disease,
             liver/kidney disease, infections including TORCHES (toxoplasmosis, rubella,
             cytomegalovirus, herpes simplex, syphilis) infections].

          -  History of an encephalopathy of unknown aetiology, occurring within 7 days following
             previous vaccination with pertussis-containing vaccine.

          -  History of transient thrombocytopenia or neurological complications (for convulsions
             or hypotonic-hyporesponsive episodes) following an earlier immunisation against
             diphtheria and/or tetanus

          -  Significant mental illness (e.g. schizophrenia, psychosis and major depression).

          -  Family history (first degree relatives only) of congenital anomalies, recurrent
             pregnancy losses (two or more consecutive losses) and unexplained neonatal death(s) in
             the subject.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required).

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine.

          -  History of febrile illness within the past 72 hours.

          -  History of physician-diagnosed or laboratory-confirmed pertussis within the past five
             years.

          -  Anything that would prevent subject from completing the study or put the subject at
             risk, as determined by the investigator.

          -  Acute disease and/or fever at the time of enrolment.

               -  Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic
                  route, or ≥ 38.0°C /100.4°F on rectal route.

               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory
                  infection) without fever may be enrolled at the discretion of the investigator.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the dose of study vaccine, or planned administration during the study
             period, with the exception of anti-D (Rh)-immunoglobulin.

          -  History of chronic excessive alcohol consumption and/or drug abuse.

        Exclusion criteria for household contacts in Spain:

          -  Child in care.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the household contact has been or will be exposed to an
             investigational or a non-investigational product (pharmaceutical product or device).

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine within 30 days preceding the dose of study vaccine, or planned use
             during the study period.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine.

          -  History of an encephalopathy of unknown aetiology, occurring within 7 days following
             previous vaccination with pertussis-containing vaccine.

          -  Acute disease and/or fever at the time of enrolment.

               -  Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic
                  route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route of recording
                  temperature will be axillary in household contacts.

               -  Household contacts with a minor illness (such as mild diarrhoea, mild upper
                  respiratory infection) without fever may be enrolled at the discretion of the
                  investigator.

          -  Anything that would put the household contact at risk, as determined by the
             investigator.

          -  Pregnant or lactating household contacts.

          -  Household contacts planning to become pregnant or planning to discontinue
             contraceptive precautions prior to 2 months post-vaccination.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3A 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Royal</city>
        <state>Quebec</state>
        <zip>H3P 3W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>613 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrava - Vitkovice</city>
        <zip>703 84</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha</city>
        <zip>14700</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antequera/Málaga</city>
        <zip>29200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aravaca</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boadilla del Monte</city>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Móstoles</city>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Perrett KP, Halperin SA, Nolan T, Martínez Pancorbo C, Tapiero B, Martinón-Torres F, Stranak Z, Virta M, Vanderkooi OG, Kosina P, Encinas Pardilla MB, Cristobal García I, Zuccotti GV, Kostanyan L, Meyer N, Ceregido MA, Cheuvart B, Kuriyakose SO, Marcos Fernández M, Rodríguez Zambrano MÁ, Martín García A, Asenjo de la Fuente JE, Camacho Marín MD, de la Calle Fernández-Miranda M, Romero Espinar Y, Marchisio PG, Manzoni P, Mesaros N. Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. Vaccine. 2020 Feb 18;38(8):2095-2104. doi: 10.1016/j.vaccine.2019.10.105. Epub 2019 Nov 24.</citation>
    <PMID>31776029</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <results_first_submitted>August 10, 2018</results_first_submitted>
  <results_first_submitted_qc>August 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2019</results_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02377349/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02377349/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 725 pregnant subjects were screened of which 690 were randomized to 2 groups. Of these, 2 subjects were withdrawn before vaccination. Therefore 688 subjects were enrolled: 1 subject was excluded from the statistical analysis, leaving 687 subjects that comprised the Total Vaccinated cohort.</recruitment_details>
      <pre_assignment_details>Safety was assessed for infants born to vaccinated subjects as well as safety of dTap vaccination in the vaccinated pregnant subjects. There was also an assessment of the acceptance rate of a single dose of Boostrix among 723 eligible household contacts of the infants born to pregnant women enrolled in Spain, as part of an assessment of cocooning.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>dTpa Group - Mother</title>
          <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
        </group>
        <group group_id="P2">
          <title>Control Group - Mother</title>
          <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="341"/>
                <participants group_id="P2" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="335"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to follow-up (partial vaccination)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to follow-up (complete vaccination)</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>dTpa Group - Mother</title>
          <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
        </group>
        <group group_id="B2">
          <title>Control Group - Mother</title>
          <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="341"/>
            <count group_id="B2" value="346"/>
            <count group_id="B3" value="687"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="4.4"/>
                    <measurement group_id="B2" value="32.5" spread="4.3"/>
                    <measurement group_id="B3" value="32.6" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African Heritage / African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic / North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Caucasian / European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="319"/>
                    <measurement group_id="B3" value="633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Concentrations Against Pertussis Toxoid Antigen (Anti-PT), Filamentous Haemagglutinin Antigen (Anti-FHA) and Pertactin Antigen (Anti-PRN) in Cord Blood Samples</title>
        <description>Antibody concentrations were assessed by Enzyme-linked immunosorbent assay (ELISA), tabulated as Geometric Mean Concentrations (GMCs) and expressed in International units per mililiter (IU/mL) for the following assay cut-offs: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.</description>
        <time_frame>At delivery - Visit 3 (anytime after 28 weeks of gestation)</time_frame>
        <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration, who had cord blood collected at least 21 days post-vaccination and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 3 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pertussis Toxoid Antigen (Anti-PT), Filamentous Haemagglutinin Antigen (Anti-FHA) and Pertactin Antigen (Anti-PRN) in Cord Blood Samples</title>
          <description>Antibody concentrations were assessed by Enzyme-linked immunosorbent assay (ELISA), tabulated as Geometric Mean Concentrations (GMCs) and expressed in International units per mililiter (IU/mL) for the following assay cut-offs: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.</description>
          <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration, who had cord blood collected at least 21 days post-vaccination and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 3 were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="41.2" upper_limit="53.3"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.8" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.1" lower_limit="329" upper_limit="407.3"/>
                    <measurement group_id="O2" value="22.7" lower_limit="19.7" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.8" lower_limit="250.9" upper_limit="362.9"/>
                    <measurement group_id="O2" value="14.6" lower_limit="12.1" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC ratio between groups (dTpa Group-Mother/Control Group-Mother) to demonstrate that maternally transferred antibodies against pertussis in the dTpa Group-Mother was superior to that in the Control Group-mother, in the cord blood sample at the time of delivery.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Criterion: The lower limit (LL) of the 95% confidence interval (CI) of the GMC ratio [dTpa Group-Mother/Control Group-Mother] for anti-PT antibodies was greater than or equal to (≥) 1.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>8.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.02</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC ratio between groups (dTpa Group-Mother/Control Group-Mother) to demonstrate that maternally transferred antibodies against pertussis in the dTpa Group-Mother was superior to that in the Control Group-mother, in the cord blood sample at the time of delivery.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Criterion: The lower limit (LL) of the 95% confidence interval (CI) of the GMC ratio [dTpa Group-Mother/Control Group-Mother] for anti-FHA antibodies was greater than or equal to (≥) 1.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>16.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.48</ci_lower_limit>
            <ci_upper_limit>19.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC ratio between groups (dTpa Group-Mother/Control Group-Mother) to demonstrate that maternally transferred antibodies against pertussis in the dTpa Group-Mother was superior to that in the Control Group-mother, in the cord blood sample at the time of delivery.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Criterion: The lower limit (LL) of the 95% confidence interval (CI) of the GMC ratio [dTpa Group-Mother/Control Group-Mother] for anti-PRN antibodies was greater than or equal to (≥) 1.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>20.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.86</ci_lower_limit>
            <ci_upper_limit>26.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects by Pregnancy Outcomes</title>
        <description>Pregnancy outcomes included live birth with no congenital anomalies, live birth with congenital anomalies, still birth with no congenital anomalies, still birth with congenital anomalies, elective termination with no congenital anomalies and elective termination with congenital anomalies. No subjects with still birth or elective termination of infant were reported.</description>
        <time_frame>From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).</time_frame>
        <population>This analysis was performed on the Total Vaccinated cohort (TVC) which included all subjects with the study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects by Pregnancy Outcomes</title>
          <description>Pregnancy outcomes included live birth with no congenital anomalies, live birth with congenital anomalies, still birth with no congenital anomalies, still birth with congenital anomalies, elective termination with no congenital anomalies and elective termination with congenital anomalies. No subjects with still birth or elective termination of infant were reported.</description>
          <population>This analysis was performed on the Total Vaccinated cohort (TVC) which included all subjects with the study vaccine administration documented.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Live infant No apparent congenital anomaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="95" upper_limit="98.8"/>
                    <measurement group_id="O2" value="97.4" lower_limit="95.1" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live infant congenital anomaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.2" upper_limit="5"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Listed Pregnancy/Neonate Related Adverse Events of Interest</title>
        <description>Listed pregnancy-related adverse events of interest/ neonate-related events of interest included gestational diabetes, pregnancy-related hypertension, premature rupture of mem-branes, preterm premature rupture of membranes, premature labour, premature uterine contractions, intrauterine growth restriction/poor foetal growth, pre-eclampsia, eclampsia, vaginal or intrauterine haemorrhage, maternal death, preterm birth, neonatal death, small for gestational age, neonatal hypoxic ischaemic encephalopathy and failure to thrive/growth deficiency were reported.</description>
        <time_frame>From Day 0 (Visit 1) to Month 2 post-delivery (Visit 4, end of the study).</time_frame>
        <population>This analysis was performed on the TVC which included all subjects with the study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Listed Pregnancy/Neonate Related Adverse Events of Interest</title>
          <description>Listed pregnancy-related adverse events of interest/ neonate-related events of interest included gestational diabetes, pregnancy-related hypertension, premature rupture of mem-branes, preterm premature rupture of membranes, premature labour, premature uterine contractions, intrauterine growth restriction/poor foetal growth, pre-eclampsia, eclampsia, vaginal or intrauterine haemorrhage, maternal death, preterm birth, neonatal death, small for gestational age, neonatal hypoxic ischaemic encephalopathy and failure to thrive/growth deficiency were reported.</description>
          <population>This analysis was performed on the TVC which included all subjects with the study vaccine administration documented.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intrauterine growth restriction/poor foetal growth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.5" upper_limit="3.4"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-eclampsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.5" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pregnancy-related hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.3" upper_limit="3"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.5" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature labour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.6" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature rupture of membranes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature uterine contractions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.1" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.2" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preterm birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.6" upper_limit="5.7"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.2" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preterm premature rupture of membranes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.3" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="0.8" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small for gestational age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.1" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal or intrauterine haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.2" upper_limit="5"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.4" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Seroprotected Subjects Against Diphteria Antigen (Anti-D), Tetanus Antigen (Anti-T) and of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN</title>
        <description>A seroprotected subject against diphteria and tetanus was a subject with antibody concentration ≥ 0.1 IU/mL. A seropositive subject was a subjects with antibody concentration ≥ 2.693 IU/mL for anti-PT, ≥ 2.046 IU/mL for anti-FHA and ≥ 2.187 IU/mL for anti-PRN.</description>
        <time_frame>One month post vaccination (Day 30) during pregnancy</time_frame>
        <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 2 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Seroprotected Subjects Against Diphteria Antigen (Anti-D), Tetanus Antigen (Anti-T) and of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN</title>
          <description>A seroprotected subject against diphteria and tetanus was a subject with antibody concentration ≥ 0.1 IU/mL. A seropositive subject was a subjects with antibody concentration ≥ 2.693 IU/mL for anti-PT, ≥ 2.046 IU/mL for anti-FHA and ≥ 2.187 IU/mL for anti-PRN.</description>
          <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 2 were available.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="289"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="95.1" upper_limit="99"/>
                    <measurement group_id="O2" value="70.6" lower_limit="65" upper_limit="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="96.6" lower_limit="93.8" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.5" upper_limit="99.6"/>
                    <measurement group_id="O2" value="61.3" lower_limit="55.5" upper_limit="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="94.5" lower_limit="91.2" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="84.5" lower_limit="79.9" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-D, Anti-T, Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</title>
        <description>Antibody concentrations were determined by ELISA, tabulated as GMCs and expressed in IU/mL.</description>
        <time_frame>One month post vaccination (Day 30) during pregnancy</time_frame>
        <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 2 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-D, Anti-T, Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</title>
          <description>Antibody concentrations were determined by ELISA, tabulated as GMCs and expressed in IU/mL.</description>
          <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 2 were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="289"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.87" upper_limit="2.57"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0.19" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" lower_limit="7.72" upper_limit="9.2"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.86" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" lower_limit="40.4" upper_limit="51.5"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.6" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.5" lower_limit="285" upper_limit="353.8"/>
                    <measurement group_id="O2" value="15" lower_limit="13.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283.6" lower_limit="237.1" upper_limit="339.1"/>
                    <measurement group_id="O2" value="10.5" lower_limit="8.7" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Vaccine Response to Anti-D and Anti-T</title>
        <description>Vaccine response for anti-D and anti-T was defined as:
for initially seronegative subjects (S-) with pre-vaccination concentration below cut-off: &lt; 0.1 IU/mL) was an antibody concentration at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL); for initially seropositive subjects (S+) with pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration.</description>
        <time_frame>One month post vaccination (Day 30) during pregnancy</time_frame>
        <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 2 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Vaccine Response to Anti-D and Anti-T</title>
          <description>Vaccine response for anti-D and anti-T was defined as:
for initially seronegative subjects (S-) with pre-vaccination concentration below cut-off: &lt; 0.1 IU/mL) was an antibody concentration at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL); for initially seropositive subjects (S+) with pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration.</description>
          <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 2 were available.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D, S-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" lower_limit="54" upper_limit="73.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D, S+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="205"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="68.1" upper_limit="81.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D, Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="288"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" lower_limit="65.5" upper_limit="76.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, S-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="73.5" upper_limit="100"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, S+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" lower_limit="61.9" upper_limit="73.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" lower_limit="63.4" upper_limit="74.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Vaccine Response to Anti-PT, Anti-FHA and Anti-PRN</title>
        <description>Vaccine response to PT, FHA and PRN antigens is defined as: for subjects with pre-vaccination antibody concentration below the assay cut-off (S-), post-vaccination anti-body concentration ≥ 4 times the assay cut-off; for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off (S+), post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and for subjects with pre-vaccination antibody concentration ≥4 times the assay cut-off (S+), post-vaccination antibody concentration ≥2 times the pre-vaccination antibody concentration.</description>
        <time_frame>One month post vaccination (Day 30) during pregnancy</time_frame>
        <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 2 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Vaccine Response to Anti-PT, Anti-FHA and Anti-PRN</title>
          <description>Vaccine response to PT, FHA and PRN antigens is defined as: for subjects with pre-vaccination antibody concentration below the assay cut-off (S-), post-vaccination anti-body concentration ≥ 4 times the assay cut-off; for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off (S+), post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and for subjects with pre-vaccination antibody concentration ≥4 times the assay cut-off (S+), post-vaccination antibody concentration ≥2 times the pre-vaccination antibody concentration.</description>
          <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 2 were available.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT, S-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="74.7" upper_limit="88.9"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT, S+ (&lt;4 cut-off)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="83.6" upper_limit="95.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT, S+ (≥4 cut-off)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="83.3" upper_limit="98.1"/>
                    <measurement group_id="O2" value="3" lower_limit="0.4" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT, Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" lower_limit="83.4" upper_limit="91.4"/>
                    <measurement group_id="O2" value="1" lower_limit="0.2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA, S-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="79.4" upper_limit="100"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA, S+ (&lt;4 cut-off)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.7" upper_limit="100"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA, S+ (≥4 cut-off)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" lower_limit="84.7" upper_limit="93.8"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.5" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA, Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="89.9" upper_limit="96"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.4" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN, S-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="73.2" upper_limit="94.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN, S+ (&lt;4 cut-off)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="89.9" upper_limit="98.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN, S+ (≥4 cut-off)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="79.5" upper_limit="91.4"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.2" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" lower_limit="85.5" upper_limit="92.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.1" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN in the Cord Blood Samples</title>
        <description>For this assay the anti-PT, anti-FHA and anti-PRN seropositivity status was determined from the cord blood samples. The seropositivity cut-offs were the following: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.</description>
        <time_frame>At delivery - Visit 3 (anytime after 27 eligible weeks of gestation)</time_frame>
        <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration, who had cord blood collected at least 21 days post-vaccination and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 3 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN in the Cord Blood Samples</title>
          <description>For this assay the anti-PT, anti-FHA and anti-PRN seropositivity status was determined from the cord blood samples. The seropositivity cut-offs were the following: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.</description>
          <population>The analysis was done on the According to protocol cohort for immunogenicity , which included all evaluable subjects who complied with the vaccine administration, who had cord blood collected at least 21 days post-vaccination and for whom data concerning antibodies against at least 1 study vaccine antigen component at Visit 3 were available.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.5" upper_limit="99.6"/>
                    <measurement group_id="O2" value="68.8" lower_limit="63.2" upper_limit="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="96.6" lower_limit="93.8" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.1" upper_limit="100"/>
                    <measurement group_id="O2" value="88" lower_limit="83.7" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Solicited Local Adverse Events (AEs)</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. &quot;Any&quot; = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
        <time_frame>During the 8-day (Day 0-Day 7) follow-up period after vaccination during pregnancy</time_frame>
        <population>The analysis was done on the TVC, which included all subjects with the study vaccine administration documented and who had returned their diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Solicited Local Adverse Events (AEs)</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. &quot;Any&quot; = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
          <population>The analysis was done on the TVC, which included all subjects with the study vaccine administration documented and who had returned their diary cards.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" lower_limit="82.1" upper_limit="89.8"/>
                    <measurement group_id="O2" value="14.6" lower_limit="11" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness (mm), Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="23.9" upper_limit="33.8"/>
                    <measurement group_id="O2" value="12.8" lower_limit="9.5" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling (mm), Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="20.5" upper_limit="30.1"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.8" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="9.2" upper_limit="16.8"/>
                    <measurement group_id="O2" value="62.7" lower_limit="57.3" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness (mm), Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="7.4" upper_limit="14.4"/>
                    <measurement group_id="O2" value="29.7" lower_limit="24.8" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling (mm), Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="3.1" upper_limit="8.3"/>
                    <measurement group_id="O2" value="26.4" lower_limit="21.7" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Solicited General AEs</title>
        <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache and fever [defined as oral, axillary or tympanic temperature ≥ 37.5 degrees Celsius (°C) or rectal temperature ≥ 38.0 °C]. &quot;Any&quot; = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
        <time_frame>During the 8-day (Day 0-Day 7) follow-up period after vaccination during pregnancy</time_frame>
        <population>The analysis was done on the TVC, which included all subjects with the study vaccine administration documented and who had returned their diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Solicited General AEs</title>
          <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache and fever [defined as oral, axillary or tympanic temperature ≥ 37.5 degrees Celsius (°C) or rectal temperature ≥ 38.0 °C]. &quot;Any&quot; = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
          <population>The analysis was done on the TVC, which included all subjects with the study vaccine administration documented and who had returned their diary cards.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" lower_limit="38.2" upper_limit="49.1"/>
                    <measurement group_id="O2" value="36.3" lower_limit="31.2" upper_limit="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal symptom, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="14" upper_limit="22.4"/>
                    <measurement group_id="O2" value="15.2" lower_limit="11.6" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="20.2" upper_limit="29.8"/>
                    <measurement group_id="O2" value="22.8" lower_limit="18.5" upper_limit="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature/(Axillary) (°C), Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.3" upper_limit="3"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.2" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" lower_limit="34.7" upper_limit="45.7"/>
                    <measurement group_id="O2" value="46.2" lower_limit="40.8" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal symptom, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="6.9" upper_limit="13.7"/>
                    <measurement group_id="O2" value="12.7" lower_limit="9.3" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="18.7" upper_limit="28.1"/>
                    <measurement group_id="O2" value="23.6" lower_limit="19.1" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature/(Axillary) (°C), Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="2.6" upper_limit="7.5"/>
                    <measurement group_id="O2" value="9.1" lower_limit="6.2" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Unsolicited AEs</title>
        <description>An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
        <time_frame>Within 31 days (Day 0 - Day 30) after each vaccination</time_frame>
        <population>The analysis was done on the TVC, which included all subjects with the study vaccine administration documented and who had returned their diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Unsolicited AEs</title>
          <description>An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.</description>
          <population>The analysis was done on the TVC, which included all subjects with the study vaccine administration documented and who had returned their diary cards.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any unsolicited AE, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="341"/>
                    <count group_id="O2" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="33.5" upper_limit="44.1"/>
                    <measurement group_id="O2" value="35.5" lower_limit="30.5" upper_limit="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any unsolicited AE, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" lower_limit="25.8" upper_limit="35.9"/>
                    <measurement group_id="O2" value="32.2" lower_limit="27.2" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Infants With Unsolicited AEs</title>
        <description>An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
        <time_frame>From delivery to Month 2 post delivery (Visit 4, end of the study).</time_frame>
        <population>The analysis was done on the TVC of Mother, which included all subjects with the study vaccine administration documented and who had returned their diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Infant</title>
            <description>This group consisted of infants born to mothers (from dTpa Group Mother) who received a dose of Boostrix during pregnancy.</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Infnat</title>
            <description>This group consisted of infants born to mothers (from Control Group Mother) who received a dose of placebo during pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Infants With Unsolicited AEs</title>
          <description>An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
          <population>The analysis was done on the TVC of Mother, which included all subjects with the study vaccine administration documented and who had returned their diary cards.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="21.8" upper_limit="31.4"/>
                    <measurement group_id="O2" value="22.3" lower_limit="18.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious AEs (SAEs)</title>
        <description>A SAE was any untoward medical occurrence that resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).</time_frame>
        <population>The analysis was done on the TVC, which included all subjects with the study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>dTpa Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Mother</title>
            <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. 27 weeks until 36 completed weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
          </group>
          <group group_id="O3">
            <title>dTpa Group - Infant</title>
            <description>This group consisted of infants born to mothers (from dTpa Group Mother) who received a dose of Boostrix during pregnancy.</description>
          </group>
          <group group_id="O4">
            <title>Control Group - Infant</title>
            <description>This group consisted of infants born to mothers (from Control Group Mother) who received a dose of placebo during pregnancy</description>
          </group>
          <group group_id="O5">
            <title>Household Group</title>
            <description>This group consisted of eligible household contacts of the infants born to pregnant women enrolled in Spain who received a single dose of Boostrix anytime during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious AEs (SAEs)</title>
          <description>A SAE was any untoward medical occurrence that resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was done on the TVC, which included all subjects with the study vaccine administration documented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="341"/>
                <count group_id="O4" value="346"/>
                <count group_id="O5" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Household Contacts of the Infants Born to Pregnant Women Vaccinated in Spain</title>
        <description>This analysis assessed the vaccination status of the household contacts (who accepted, received or refused vaccination) and also the reasons for refusal (not coming to site, refused to be vaccinated, unspecified) as part of an assessment of cocooning among the eligible household contacts.</description>
        <time_frame>From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).</time_frame>
        <population>This analysis was done on the Total cohort for household contacts in Spain, which included all eligible household contacts of the infants born to pregnant women vaccinated in Spain.</population>
        <group_list>
          <group group_id="O1">
            <title>Household Group</title>
            <description>This group consisted of eligible household contacts of the infants born to pregnant women enrolled in Spain who received a single dose of Boostrix anytime during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Household Contacts of the Infants Born to Pregnant Women Vaccinated in Spain</title>
          <description>This analysis assessed the vaccination status of the household contacts (who accepted, received or refused vaccination) and also the reasons for refusal (not coming to site, refused to be vaccinated, unspecified) as part of an assessment of cocooning among the eligible household contacts.</description>
          <population>This analysis was done on the Total cohort for household contacts in Spain, which included all eligible household contacts of the infants born to pregnant women vaccinated in Spain.</population>
          <units>Percentage of household contacts</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Accepted vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="81.5" upper_limit="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1" lower_limit="81.2" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refused vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="13.1" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not coming to site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.7" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refused to be vaccinated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="11" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Household Contacts With SAEs</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
        <time_frame>During the 31-day (Days 0-30) follow-up period post-vaccination (Boostrix administered preferably 2 weeks before the birth of the infant, Visit 3).</time_frame>
        <population>This analysis was done on the Total cohort for household contacts which included all eligible household contacts of the infants born to pregnant women vaccinated in Spain. For the analysis of safety, all vaccinated household contacts are considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Household Group</title>
            <description>This group consisted of eligible household contacts of the infants born to pregnant women enrolled in Spain who received a single dose of Boostrix anytime during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Household Contacts With SAEs</title>
          <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
          <population>This analysis was done on the Total cohort for household contacts which included all eligible household contacts of the infants born to pregnant women vaccinated in Spain. For the analysis of safety, all vaccinated household contacts are considered.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="723"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the Mothers` Groups: Solicited local and general AEs were reported during Days 0 - 7 following each dose. Unsolicited AEs were reported during Days 0 - 30 following each dose. SAEs were reported during the entire study period (Day 0 up to Month 2). For the Infants` Groups: unsolicited AEs and SAEs were reported From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study). For the Household Group: SAEs were reported during the 31-day (Days 0-30) follow-up period post-vaccination.</time_frame>
      <desc>No solicited symptoms were assessed for the Infants` Groups and Household Group.</desc>
      <group_list>
        <group group_id="E1">
          <title>dTpa Group-Mother</title>
          <description>This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours).</description>
        </group>
        <group group_id="E2">
          <title>Control Group-Mother</title>
          <description>This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours).</description>
        </group>
        <group group_id="E3">
          <title>dTpa Group - Infant</title>
          <description>This group consisted of infants born to mothers (from dTpa Group Mother) who received a dose of Boostrix during pregnancy.</description>
        </group>
        <group group_id="E4">
          <title>Control Group-Infant</title>
          <description>This group consisted of infants born to mothers (from Control Group Mother) who received a dose of placebo during pregnancy</description>
        </group>
        <group group_id="E5">
          <title>Household Group</title>
          <description>This group consisted of eligible household contacts of the infants born to pregnant women enrolled in Spain who received a single dose of Boostrix anytime during the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="341"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="346"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="341"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="346"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Isoimmune haemolytic disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Cardiac septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Congenital cardiovascular anomaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Congenital hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypospadias</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Microtia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Polydactyly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Syndactyly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Transposition of the great vessels</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="341"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amniotic cavity infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Neonatal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Perineal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Neonatal hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Somnolence neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Foetal growth restriction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hellp syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Large for dates baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Placenta praevia haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Polyhydramnios</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="341"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="341"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="341"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="341"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Preterm premature rupture of membranes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Retained placenta or membranes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Small for dates baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Uterine contractions during pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Uterine atony</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Meconium aspiration syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="341"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="321" subjects_at_risk="341"/>
                <counts group_id="E2" subjects_affected="303" subjects_at_risk="346"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="341"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="346"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="341"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Thyroid dysfunction in pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Eczema eyelids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="341"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="341"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="92" subjects_affected="78" subjects_at_risk="341"/>
                <counts group_id="E2" events="95" subjects_affected="83" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="341"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="276" subjects_affected="188" subjects_at_risk="341"/>
                <counts group_id="E2" events="277" subjects_affected="186" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="130" subjects_affected="106" subjects_at_risk="341"/>
                <counts group_id="E2" events="142" subjects_affected="117" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="330" subjects_affected="290" subjects_at_risk="341"/>
                <counts group_id="E2" events="258" subjects_affected="223" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="101" subjects_affected="91" subjects_at_risk="341"/>
                <counts group_id="E2" events="99" subjects_affected="92" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="341"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis of pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amniotic cavity infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="341"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Genital infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="341"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Mastitis postpartum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="341"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nipple infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="341"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="346"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="341"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Suture rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cow's milk intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="341"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Ligament pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="169" subjects_affected="129" subjects_at_risk="341"/>
                <counts group_id="E2" events="169" subjects_affected="126" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Afterbirth pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="341"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Cervical dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Labour pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Small for dates baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Traumatic delivery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Uterine contractions during pregnancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Uterine hypotonus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Uterine irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Urethral prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast engorgement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Breast inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Cervical discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nipple inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Suppressed lactation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Uterine pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Varicose veins vulval</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="341"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Grunting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="341"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="608"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>en736091@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

